Neuren Pharmaceuticals Limited (NURPF)

Market Cap	1.21B +6.1%
Revenue (ttm)	143.49M +12.1%
Net Income	97.72M +27.1%
EPS	0.75 +28.3%
Shares Out	n/a
PE Ratio	12.39
Forward PE	75.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,214
Open	9.86
Previous Close	9.86
Day's Range	9.86 - 9.86
52-Week Range	6.60 - 14.80
Beta	1.74
RSI	42.37
Earnings Date	Feb 27, 2026

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: NURPF

Financial Performance

In 2024, Neuren Pharmaceuticals's revenue was 216.83 million, a decrease of -6.51% compared to the previous year's 231.94 million. Earnings were 142.04 million, a decrease of -9.57%.

Financial numbers in AUD